A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Eluminate-1
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus (Eluminate-1)
2 other identifiers
interventional
800
13 countries
149
Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 type-2-diabetes-mellitus
Started Jul 2026
Typical duration for phase_3 type-2-diabetes-mellitus
149 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 18, 2026
CompletedFirst Posted
Study publicly available on registry
June 23, 2026
CompletedStudy Start
First participant enrolled
July 6, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 14, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 14, 2028
July 15, 2026
July 1, 2026
2 years
June 18, 2026
July 14, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change from baseline in Hemoglobin A1c (HbA1c)
Baseline to Week 40
Secondary Outcomes (8)
Achievement of HbA1c < 7% (53 mmol/mol)
Week 40
Achievement of HbA1c ≤ 6.5% (48 mmol/mol)
Week 40
Percent change in body weight
Baseline to Week 40
Change from baseline in body weight
Baseline to Week 40
Change from baseline in Systolic Blood Pressure (SBP)
Baseline to Week 40
- +3 more secondary outcomes
Study Arms (4)
Elecoglipron dose level 1 + dapagliflozin-matched placebo
EXPERIMENTALParticipants will receive elecoglipron at dose level 1 and dapagliflozin-matched placebo, administered orally once daily.
Elecoglipron dose level 2 + dapagliflozin-matched placebo
EXPERIMENTALParticipants will receive elecoglipron at dose level 2 and dapagliflozin-matched placebo, administered orally once daily.
Elecoglipron (one of the studied dose levels) + dapagliflozin
EXPERIMENTALParticipants will receive elecoglipron at one of the study dose levels in combination with dapagliflozin, administered orally once daily.
Elecoglipron-matched placebo + dapagliflozin-matched placebo
PLACEBO COMPARATORParticipants will receive elecoglipron-matched placebo and dapagliflozin-matched placebo, administered orally once daily.
Interventions
Elecoglipron is administered orally once daily.
Dapagliflozin administered orally once daily.
A placebo matching elecoglipron, administered orally once daily.
A placebo matching dapagliflozin, administered orally once daily.
Eligibility Criteria
You may qualify if:
- Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
- T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication
- HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
- Body mass index (BMI) of ≥ 23 kg/m2 at screening
- Stable body weight (self-reported or documented) for 90 days prior to screening
You may not qualify if:
- Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
- Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
- Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
- Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
- History of acute or chronic pancreatitis
- Severe congestive heart failure (New York Heart Association IV)
- History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (149)
Research Site
Birmingham, Alabama, 35233, United States
Research Site
Daphne, Alabama, 36526, United States
Research Site
Lomita, California, 90717, United States
Research Site
Los Alamitos, California, 90720, United States
Research Site
San Diego, California, 92111, United States
Research Site
Walnut Creek, California, 94598, United States
Research Site
Englewood, Colorado, 80110, United States
Research Site
Bridgeport, Connecticut, 06606, United States
Research Site
Jacksonville, Florida, 32256, United States
Research Site
Orlando, Florida, 32801, United States
Research Site
Conyers, Georgia, 30094, United States
Research Site
Decatur, Georgia, 30030, United States
Research Site
Hinesville, Georgia, 31313, United States
Research Site
El Dorado, Kansas, 67042, United States
Research Site
Newton, Kansas, 67114, United States
Research Site
Lexington, Kentucky, 40509, United States
Research Site
Covington, Louisiana, 70433, United States
Research Site
Bowie, Maryland, 20715, United States
Research Site
Southfield, Michigan, 48075, United States
Research Site
Kansas City, Missouri, 64111, United States
Research Site
St Louis, Missouri, 63141, United States
Research Site
Las Vegas, Nevada, 89119, United States
Research Site
Anderson, South Carolina, 29621, United States
Research Site
Knoxville, Tennessee, 37909, United States
Research Site
Fort Worth, Texas, 76135, United States
Research Site
Irving, Texas, 75061, United States
Research Site
Renton, Washington, 98057, United States
Research Site
Buenos Aires, C1425AGC, Argentina
Research Site
CABA, C1120AAC, Argentina
Research Site
Caba, C1128AAF, Argentina
Research Site
Ciudad de Buenos Aires, C1094AAD, Argentina
Research Site
Mar del Plata, B7600GNY, Argentina
Research Site
San Nicolás, B2900DMH, Argentina
Research Site
San Vicente, 5006, Argentina
Research Site
Santa Fe, S3000FWO, Argentina
Research Site
Baotou, 014030, China
Research Site
Binzhou, 256606, China
Research Site
Cangzhou, 061002, China
Research Site
Changsha, 430033, China
Research Site
Chengdu, 610081, China
Research Site
Ganzhou, 341099, China
Research Site
Haikou, 570208, China
Research Site
Hangzhou, 310006, China
Research Site
Huangshi, 435000, China
Research Site
Huzhou, 313003, China
Research Site
Jinan, 250013, China
Research Site
Jinzhou, 121002, China
Research Site
Lanzhou, 730000, China
Research Site
Lianyungang, 222023, China
Research Site
Liaocheng, 252000, China
Research Site
Liuzhou, 545006, China
Research Site
Loudi, 417099, China
Research Site
Luoyang, 471001, China
Research Site
Luoyang, 471003, China
Research Site
Nanchang, 330006, China
Research Site
Nanjing, 2100008, China
Research Site
Nanjing, 211100, China
Research Site
Nanyang, 473000, China
Research Site
Ningbo, 315010, China
Research Site
Panjin, 124000, China
Research Site
Qingdao, 266035, China
Research Site
Sanmenxia, 472000, China
Research Site
Shanghai, 200040, China
Research Site
Suining Shi, 629000, China
Research Site
Tonghua, 134000, China
Research Site
Xi'an, 710077, China
Research Site
Xiangtan, 411100, China
Research Site
Xuancheng, 242000, China
Research Site
Yibin, 610500, China
Research Site
Yichang, 443003, China
Research Site
Yuncheng, 044099, China
Research Site
Zhengzhou, 450002, China
Research Site
Zhengzhou, 450012, China
Research Site
Zhenjiang, 212002, China
Research Site
Gandrup, 9362, Denmark
Research Site
Herlev, 2730, Denmark
Research Site
Hillerød, 3400, Denmark
Research Site
Hvidovre, 2650, Denmark
Research Site
Athens, 10676, Greece
Research Site
Athens, 11526, Greece
Research Site
Athens, 12131, Greece
Research Site
Athens, 15125, Greece
Research Site
Heraklion, 71500, Greece
Research Site
Piraeus, 18454, Greece
Research Site
Thessaloniki, 54636, Greece
Research Site
Thessaloniki, 57001, Greece
Research Site
Thessaloniki, 57010, Greece
Research Site
Budapest, 1027, Hungary
Research Site
Budapest, 1036, Hungary
Research Site
Budapest, 1138, Hungary
Research Site
Debrecen, 4032, Hungary
Research Site
Dunaújváros, 2400, Hungary
Research Site
Szeged, 6725, Hungary
Research Site
Szolnok, 5000, Hungary
Research Site
Amagasaki-shi, 660-8550, Japan
Research Site
Chiba, 261-0004, Japan
Research Site
Chitose-shi, 066-0032, Japan
Research Site
Chūōku, 1040031, Japan
Research Site
Koga-shi, 306-0232, Japan
Research Site
Minatoku, 105-0004, Japan
Research Site
Okayama, 701-1192, Japan
Research Site
Oyama-shi, 323-0022, Japan
Research Site
Shinjuku-ku, 169-0072, Japan
Research Site
Zentsuji-shi, 765-0071, Japan
Research Site
Bratislava, 81108, Slovakia
Research Site
Bratislava, 831 03, Slovakia
Research Site
Košice, 04001, Slovakia
Research Site
Martin, 036 01, Slovakia
Research Site
Námestovo, 02901, Slovakia
Research Site
Poprad, 05845, Slovakia
Research Site
Rožňava, 048 01, Slovakia
Research Site
Brackenfell, 7560, South Africa
Research Site
Cape Town, 7500, South Africa
Research Site
Cape Town, 7570, South Africa
Research Site
Claremont, 7708, South Africa
Research Site
Durban, 4093, South Africa
Research Site
eMkhomazi, 4170, South Africa
Research Site
Johannesburg, 1827, South Africa
Research Site
KwaDukuza, 4449, South Africa
Research Site
Paarl, 7646, South Africa
Research Site
Pretoria, 2, South Africa
Research Site
Jongno-gu, 110-746, South Korea
Research Site
Seongnam-si, 463-712, South Korea
Research Site
Seoul, 03080, South Korea
Research Site
Seoul, 5505, South Korea
Research Site
Barcelona, 08016, Spain
Research Site
Barcelona, 08020, Spain
Research Site
Barcelona, 08035, Spain
Research Site
Barcelona, 08930, Spain
Research Site
Figueres, 17600, Spain
Research Site
Seville, 41003, Spain
Research Site
Seville, 41950, Spain
Research Site
Changhua, 500, Taiwan
Research Site
Kaohsiung City, 80756, Taiwan
Research Site
Kaohsiung City, 813, Taiwan
Research Site
New Taipei City, 220, Taiwan
Research Site
Taichung, 40201, Taiwan
Research Site
Taichung, 40705, Taiwan
Research Site
Taichung, 433004, Taiwan
Research Site
Tainan, 70403, Taiwan
Research Site
Tainan County, 71044, Taiwan
Research Site
Taipei, 10002, Taiwan
Research Site
Adana, 01060, Turkey (Türkiye)
Research Site
Ankara, 06530, Turkey (Türkiye)
Research Site
Ankara, 06560, Turkey (Türkiye)
Research Site
Bursa, 16310, Turkey (Türkiye)
Research Site
Izmir, 35340, Turkey (Türkiye)
Research Site
Kayseri, 38039, Turkey (Türkiye)
Research Site
Samsun, 55139, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 18, 2026
First Posted
June 23, 2026
Study Start
July 6, 2026
Primary Completion (Estimated)
July 14, 2028
Study Completion (Estimated)
July 14, 2028
Last Updated
July 15, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.